Hostname: page-component-586b7cd67f-gb8f7 Total loading time: 0 Render date: 2024-11-23T15:42:36.276Z Has data issue: false hasContentIssue false
  • English
  • Français
Accepted manuscript

Butyrate attenuates high-fat diet induced glomerulopathy through GPR43-Sirt3 pathway

Published online by Cambridge University Press:  22 November 2024

Ying Shi ,
Lin Xing ,
Ruoyi Zheng ,
Xin Luo ,
Fangzhi Yue ,
Xingwei Xiang ,
Anqi Qiu ,
Junyan Xie ,
Ryan Russell  and
Dongmei Zhang Open the ORCID record for Dongmei Zhang [Opens in a new window]
Ying Shi
Affiliation:
Department of Endocrinology, Xiangya Hospital, Central South University, Changsha, China.
Lin Xing
Affiliation:
Department of Endocrinology, Xiangya Hospital, Central South University, Changsha, China.
Ruoyi Zheng
Affiliation:
Department of Endocrinology, Xiangya Hospital, Central South University, Changsha, China.
Xin Luo
Affiliation:
Department of Endocrinology, Xiangya Hospital, Central South University, Changsha, China.
Fangzhi Yue
Affiliation:
Department of Endocrinology, Xiangya Hospital, Central South University, Changsha, China.
Xingwei Xiang
Affiliation:
Department of Endocrinology, Xiangya Hospital, Central South University, Changsha, China.
Anqi Qiu
Affiliation:
Department of Endocrinology, Xiangya Hospital, Central South University, Changsha, China.
Junyan Xie
Affiliation:
Department of Endocrinology, Xiangya Hospital, Central South University, Changsha, China.
Ryan Russell
Affiliation:
Department of Health and Human Performance, College of Health Professions, University of Texas Rio Grande Valley, Brownsville, Texas.
Dongmei Zhang*
Affiliation:
Department of Endocrinology, Xiangya Hospital, Central South University, Changsha, China. Hunan Engineering Research Center for Obesity and its Metabolic Complications, Xiangya Hospital, Central South University, Changsha, China.
*
*Correspondence: Dongmei Zhang, PhD, MD, Department of Endocrinology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha 410008, China. Tel: (86) 731-89753727. Fax: (86) 731-84327166. E-mail: [email protected]
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The incidence of obesity related glomerulopathy (ORG) is rising worldwide with very limited treatment methods. Paralleled with the gut-kidney axis theory, beneficial effects of butyrate, one of short-chain fatty acids produced by gut microbiota, on metabolism and certain kidney diseases have gained growing attention. However, the effects of butyrate on ORG and its underlying mechanism are largely unexplored. In this study, a mice model of ORG was established with high-fat diet (HFD) feeding for 16 weeks, and sodium butyrate treatment was initiated at the 8th week. Podocytes injury, oxidative stress, and mitochondria function were evaluated in mice kidney and validated in vitro in palmitic acid (PA) treated-MPC5 cells. Further, the molecular mechanisms of butyrate on podocytes were explored. Compared with controls, sodium butyrate treatment alleviated kidney injuries and renal oxidative stress in HFD-fed mice. In MPC5 cells, butyrate ameliorated PA-induced podocyte damage and helped maintain the structure and function of the mitochondria. Moreover, the effects of butyrate on podocytes were mediated via GPR43-Sirt3 signal pathway, as evidenced by the diminished effects of butyrate with the intervention of GPR43 or Sirt3 inhibitors. In summary, we conclude that butyrate has therapeutic potential for the treatment of ORG. It attenuates HFD-induced ORG and podocytes injuries through the activation of GPR43-Sirt3 signaling pathway.

Keywords

butyratemitochondriaobesity related glomerulopathypodocytes
Type
Research Article
Information
British Journal of Nutrition , Accepted manuscript , pp. 1 - 27
Copyright
© The Authors 2024